Monday May 7 | AmericanBankingNews.com
Standpoint Research Analysts Begin Coverage on Hi-Tech Pharmacal
The firm set a "buy" rating and a $43.00 price target on the stock. Other equities research analysts have also recently issued reports about the stock.
Hi-Tech Pharmacal Licenses Rights to Lidocaine 5% Ointment
HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia AMITYVILLE, N.Y.-- --Hi-Tech Pharmacal Co., Inc.